Difference between revisions of "Tivozanib (Fotivda)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "==Diseases for which it is established==" to "==Diseases for which it is established ''(work in progress)''==") |
||
| Line 2: | Line 2: | ||
From the [http://www.cancer.gov/publications/dictionaries/cancer-drug?CdrID=561728 NCI Drug Dictionary]: An orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities. Tivozanib binds to and inhibits VEGFRs 1, 2 and 3, which may result in the inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis and tumor cell death.<ref name="insert">[https://www.fotivdahcp.com/fotivdapi.pdf Tivozanib (Fotivda) package insert]</ref><ref>[[:File:Tivozanib.pdf | Tivozanib (Fotivda) package insert (locally hosted backup)]]</ref><ref>[https://www.fotivda.com/ Fotivda manufacturer's website]</ref> | From the [http://www.cancer.gov/publications/dictionaries/cancer-drug?CdrID=561728 NCI Drug Dictionary]: An orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities. Tivozanib binds to and inhibits VEGFRs 1, 2 and 3, which may result in the inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis and tumor cell death.<ref name="insert">[https://www.fotivdahcp.com/fotivdapi.pdf Tivozanib (Fotivda) package insert]</ref><ref>[[:File:Tivozanib.pdf | Tivozanib (Fotivda) package insert (locally hosted backup)]]</ref><ref>[https://www.fotivda.com/ Fotivda manufacturer's website]</ref> | ||
| − | ==Diseases for which it is established== | + | ==Diseases for which it is established ''(work in progress)''== |
*[[Renal cell carcinoma]] | *[[Renal cell carcinoma]] | ||
Revision as of 12:15, 26 May 2022
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities. Tivozanib binds to and inhibits VEGFRs 1, 2 and 3, which may result in the inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis and tumor cell death.[1][2][3]
Diseases for which it is established (work in progress)
Patient drug information
History of changes in FDA approval
- 3/10/2021: Approved for adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.
Also known as
- Code name: AV-951
- Brand name: Fotivda